Increase in serum uric acid level associated with cisplatin therapy. Correlation with liver but not kidney platinum concentrations.
Hyperuricemia associated with cisplatin therapy is considered to be a consequence of cisplatin-induced nephrotoxic reactions. We correlated changes in serum uric acid levels in patients with malignant neoplasms with tissue levels of platinum and the total dose of cisplatin. In 15 patients, the serum uric acid level increased from 6.1 +/- 1.0 mg/dL to 8.3 +/- 1.3 mg/dL during the time they were receiving cisplatin therapy. The change in uric acid level from baseline to peak correlated with both the total dose of cisplatin and the liver platinum concentration. There was no correlation with platinum concentration in the renal cortex and medulla.
D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007668:Kidney / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D009362:Neoplasm Metastasis; D010984:Platinum / Q000378:metabolism*; D013997:Time Factors; D014527:Uric Acid / Q000097:blood*
D014527:Uric Acid; D010984:Platinum; D002945:Cisplatin